Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid vs. Quixil - Reducing Blood Loss in Joint Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who are to undergo elective hip or knee joint replacement~* Must be cemented arthroplasty~* Must be primary arthroplasty~Exclusion Criteria:~* Uncemented arthroplasty.~* Revision arthroplasty.~* Patients on anticoagulant (warfarin, low molecular weight heparin) or other medication known to affect clotting (except aspirin, which is to be given as part of standard DVT prophylaxis in all cases).~* Other drugs that may affect the activity of the drugs under investigation.~* Allergy to asprin (all patients to receive 150mg aspirin as standard DVT prophylaxis for 6 weeks).~* Patients with known coagulopathy (APTT or PT outside normal range pre-operatively).~* Previous reaction or ethical/religious objection to receiving blood products (Quixil contains a derivative of human blood).~* Pregnancy or breastfeeding.~* Patients who have a past medical history of thrombo-embolism at any time.~* Patients who need intravenous fluid administration for greater than 24 hours following operation.~* Patients who need allogenic blood transfusion within study period.~* Jehovah's Witnesses, or any other group of patients with ethical objections to receiving blood products.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).